Log in
Enquire now
‌

US Patent 7052695 Angiopoietins and methods of treating hypertension

Patent 7052695 was granted and assigned to Regeneron Pharmaceuticals on May, 2006 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
70526950
Patent Inventor Names
Susan Croll Kalish0
Date of Patent
May 30, 2006
0
Patent Application Number
102742220
Date Filed
October 18, 2002
0
Patent Citations Received
‌
US Patent 12076033 Ablation device with optimized input power profile and method of using the same
0
‌
US Patent 12064420 Tie-2 activators targeting the Schlemm's canal
0
‌
US Patent 12133765 Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery
0
‌
US Patent 12102845 Ultrasound-based neuromodulation system
0
‌
US Patent 11998266 Intravascular energy delivery
0
0
Patent Primary Examiner
‌
Lorraine Spector
0
Patent abstract

The invention generally relates to angiogenic factors and more particularly to the angiopoietin family of growth factors and to methods of using these growth factors to induce vasodilation and hypotension and reducing hypertension.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7052695 Angiopoietins and methods of treating hypertension

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.